AR098347A2 - USE OF FENTANIL ORAL EFERVESCENT DOSAGE - Google Patents
USE OF FENTANIL ORAL EFERVESCENT DOSAGEInfo
- Publication number
- AR098347A2 AR098347A2 ARP140104200A ARP140104200A AR098347A2 AR 098347 A2 AR098347 A2 AR 098347A2 AR P140104200 A ARP140104200 A AR P140104200A AR P140104200 A ARP140104200 A AR P140104200A AR 098347 A2 AR098347 A2 AR 098347A2
- Authority
- AR
- Argentina
- Prior art keywords
- fentanyl
- cmáx
- dosage form
- dosage
- oral
- Prior art date
Links
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 title abstract 5
- 229960002428 fentanyl Drugs 0.000 title abstract 5
- 239000002552 dosage form Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000002200 mouth mucosa Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940071117 starch glycolate Drugs 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso de una forma de dosificación que comprende entre 100 y 800 mg de fentanilo, calculado como base libre de fentanilo o una cantidad equivalente de una sal del mismo, compuestos para efervescencia, una sustancia para ajustar el pH donde dicha sustancia se selecciona y provee en una cantidad capaz de proporcionar un cambio en el pH localizado de al menos 0,5 unidades de pH, y un almidón glicolato, donde dicha forma de dosificación es adecuada para la distribución de dicho fentanilo a través de la mucosa oral de un paciente mediante administración bucal, gingival o sublingual, y proveer una relación de Cₘáˣ a dosis entre 2,0 y 4,0 pg/ml/mg una relación lineal entre las dosis y Cₘáˣ, o una Cₘáˣ que es comparable a la de una forma de dosificación ACTlQ® que contiene aproximadamente 80% más fentanilo, para la fabricación de un medicamento para el tratamiento del dolor.Use of a dosage form comprising between 100 and 800 mg of fentanyl, calculated as fentanyl free base or an equivalent amount of a salt thereof, effervescent compounds, a substance to adjust the pH where said substance is selected and provided in an amount capable of providing a change in the localized pH of at least 0.5 pH units, and a starch glycolate, wherein said dosage form is suitable for the distribution of said fentanyl through the oral mucosa of a patient by administration buccal, gingival or sublingual, and provide a ratio of Cₘáˣ at doses between 2.0 and 4.0 pg / ml / mg a linear relationship between doses and Cₘáˣ, or a Cₘáˣ that is comparable to that of an ACTlQ dosage form ® containing approximately 80% more fentanyl, for the manufacture of a medication for the treatment of pain.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61566504P | 2004-10-04 | 2004-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098347A2 true AR098347A2 (en) | 2016-05-26 |
Family
ID=48471142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104200A AR098347A2 (en) | 2004-10-04 | 2014-11-07 | USE OF FENTANIL ORAL EFERVESCENT DOSAGE |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR098347A2 (en) |
| TW (1) | TWI387466B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030091629A1 (en) | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| MXPA06007453A (en) | 2003-12-31 | 2007-01-31 | Cima Labs Inc | Effervescent oral opiate dosage form. |
| KR101184138B1 (en) | 2003-12-31 | 2012-09-19 | 시마 랩스 인크. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
-
2005
- 2005-03-09 TW TW94107160A patent/TWI387466B/en not_active IP Right Cessation
-
2014
- 2014-11-07 AR ARP140104200A patent/AR098347A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200611697A (en) | 2006-04-16 |
| TWI387466B (en) | 2013-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE433745T1 (en) | TABLET FOR BUCCAL, SUBLINGUAL OR GINGIVAL ADMINISTRATION, CONTAINING AN EFFORTABLE MIXTURE | |
| AR098347A2 (en) | USE OF FENTANIL ORAL EFERVESCENT DOSAGE | |
| CO6160321A2 (en) | USE OF 2-6- (3-AMINO-PIPERIDIN-1-IL) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PYRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILE | |
| IL176449A0 (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| AR059723A2 (en) | COMPOSITION OF HIGH DOSE OF IBANDRONATO | |
| CO5261517A1 (en) | ANALGESIC PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENORFINE / NALOXONE, BUPRENORFINE / NALTREXONE OR BUPRENORPHINE / NALMEFEN IN LOW DOSE | |
| JP2007517053A5 (en) | ||
| NO20043723L (en) | Pharmaceutical dosage form for delivery through mucosa | |
| AR060836A1 (en) | A TRANS-MUCOSA DISK TO ADMINISTER AN ACTIVE AGENT, A TRANS-MUCOSA COMPOSITION AND THE METHOD OF ADMINISTRATION OBTAINED | |
| CY1106574T1 (en) | MYO-INOSITOL HEXAPHOSPHORATE FOR TOPICAL USE | |
| AR045972A1 (en) | FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS | |
| BR0316364A (en) | Combination of cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
| AR065581A1 (en) | IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME | |
| PE20060002A1 (en) | ANTINEOPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| PT1383752E (en) | 3-PIPERIDINOPROPYOPHENONES DETERMINED AS WELL AS PHARMACONS CONTAINING THESE COMPOUNDS | |
| ATE499939T1 (en) | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN POLYMORPHO A | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| ATE339224T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING HONEY FOR WOUND TREATMENT | |
| ES2175663T3 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS. | |
| MXPA05005781A (en) | Combination of ibuprofen and oxycodone for acute pain relief. | |
| CO5640120A2 (en) | FORMULATION AND METHODS FOR THE TROMBOCITEMIA TREATMENT | |
| ES2811799T3 (en) | Use of statins for periodontal disease and bone regeneration | |
| HRP20080255A2 (en) | USE OF CYCLETHANINE AND OTHER FUROPYRIDINS FOR THE TREATMENT OF PRINCIPLE SYSTOLIC HYPERTENSION, ISOLATED SYSTOLIC HYPERTENSION, INCREASED PULSE PRESSURE AND GENERAL HYPERTENSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |